234 related articles for article (PubMed ID: 33278804)
1. Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Aoki J; Iguchi Y; Urabe T; Yamagami H; Todo K; Fujimoto S; Idomari K; Kaneko N; Iwanaga T; Terasaki T; Tanaka R; Yamamoto N; Tsujino A; Nomura K; Abe K; Uno M; Okada Y; Matsuoka H; Yamagata S; Yamamoto Y; Yonehara T; Inoue T; Yagita Y; Kimura K;
J Stroke Cerebrovasc Dis; 2021 Feb; 30(2):105494. PubMed ID: 33278804
[TBL] [Abstract][Full Text] [Related]
2. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
[TBL] [Abstract][Full Text] [Related]
3. Cilostazol addition to aspirin may worsen the short-term outcome in patients with large artery disease: ADS subanalysis.
Aoki J; Kimura K;
J Neurol Sci; 2024 Jan; 456():122854. PubMed ID: 38154248
[TBL] [Abstract][Full Text] [Related]
4. Tachycardia Changes Increase Neurological Deterioration in Patients with Acute Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis.
Matsuzono K; Fujimoto S; Aoki J; Ozawa T; Kimura K
J Atheroscler Thromb; 2023 Jan; 30(1):66-73. PubMed ID: 35283411
[TBL] [Abstract][Full Text] [Related]
5. Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset.
Aoki J; Iguchi Y; Urabe T; Yamagami H; Todo K; Fujimoto S; Idomari K; Kaneko N; Iwanaga T; Terasaki T; Tanaka R; Yamamoto N; Tsujino A; Nomura K; Abe K; Uno M; Okada Y; Matsuoka H; Yamagata S; Yamamoto Y; Yonehara T; Inoue T; Yagita Y; Kimura K;
J Am Heart Assoc; 2019 Aug; 8(15):e012652. PubMed ID: 31347430
[TBL] [Abstract][Full Text] [Related]
6. Microbleeds and clinical outcome in acute mild stroke patients treated with antiplatelet therapy: ADS post-hoc analysis.
Aoki J; Iguchi Y; Urabe T; Yamagami H; Todo K; Fujimoto S; Idomari K; Kaneko N; Iwanaga T; Terasaki T; Tanaka R; Yamamoto N; Tsujino A; Nomura K; Abe K; Uno M; Okada Y; Matsuoka H; Yamagata S; Yamamoto Y; Yonehara T; Inoue T; Yagita Y; Kimura K
J Clin Neurosci; 2021 Jul; 89():216-222. PubMed ID: 34119270
[TBL] [Abstract][Full Text] [Related]
7. Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation.
Dai C; Chen Z; Fu J; Qian J; Ge J
Thromb Haemost; 2020 May; 120(5):857-865. PubMed ID: 32369856
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Lin MP; Meschia JF; Gopal N; Barrett KM; Ross OA; Ertekin-Taner N; Brott TG
J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105581. PubMed ID: 33388632
[TBL] [Abstract][Full Text] [Related]
9. Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Uchiyama S; Toyoda K; Okamura S; Omae K; Hoshino H; Kimura K; Kitagawa K; Minematsu K; Yamaguchi T
Int J Stroke; 2023 Apr; 18(4):426-432. PubMed ID: 35762581
[TBL] [Abstract][Full Text] [Related]
10. Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis.
Toyoda K; Omae K; Hoshino H; Uchiyama S; Kimura K; Miwa K; Minematsu K; Yamaguchi K; Suda Y; Toru S; Kitagawa K; Ihara M; Koga M; Yamaguchi T;
Neurology; 2022 Mar; 98(10):e983-e992. PubMed ID: 35074890
[TBL] [Abstract][Full Text] [Related]
11. Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Nishiyama Y; Kimura K; Otsuka T; Toyoda K; Uchiyama S; Hoshino H; Sakai N; Okada Y; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Minematsu K; Matsumoto M; Tominaga T; Tomimoto H; Terayama Y; Yasuda S; Yamaguchi T;
Stroke; 2023 Mar; 54(3):697-705. PubMed ID: 36734235
[TBL] [Abstract][Full Text] [Related]
12. Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com.
Hoshino H; Toyoda K; Omae K; Takahashi K; Uchiyama S; Kimura K; Yamaguchi K; Minematsu K; Origasa H; Yamaguchi T
J Atheroscler Thromb; 2023 Jun; 30(6):675-683. PubMed ID: 36070920
[TBL] [Abstract][Full Text] [Related]
13. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
Lee YS; Bae HJ; Kang DW; Lee SH; Yu K; Park JM; Cho YJ; Hong KS; Kim DE; Kwon SU; Lee KB; Rha JH; Koo J; Han MG; Lee SJ; Lee JH; Jung SW; Lee BC; Kim JS
Cerebrovasc Dis; 2011; 32(1):65-71. PubMed ID: 21613787
[TBL] [Abstract][Full Text] [Related]
14. Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Guo JJ; Xu E; Lin QY; Zeng GL; Xie HF
Neurosci Bull; 2009 Dec; 25(6):383-90. PubMed ID: 19927175
[TBL] [Abstract][Full Text] [Related]
15. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Toyoda K; Uchiyama S; Hoshino H; Kimura K; Origasa H; Naritomi H; Minematsu K; Yamaguchi T;
Int J Stroke; 2015 Feb; 10(2):253-8. PubMed ID: 25487817
[TBL] [Abstract][Full Text] [Related]
16. Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial.
Bulwa Z; Saleh Velez FG; Brorson JR; Pinto CB
J Stroke Cerebrovasc Dis; 2020 Nov; 29(11):105115. PubMed ID: 33066893
[TBL] [Abstract][Full Text] [Related]
17. Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis.
Uchiyama S; Toyoda K; Omae K; Saita R; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K; Matsumoto M; Tominaga T; Tomimoto H; Terayama Y; Yasuda S; Yamaguchi T
J Am Heart Assoc; 2021 Oct; 10(20):e022575. PubMed ID: 34622679
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial.
Lee CH; Lee JY; Park GM; Lee SW; Kim HS; Choi YJ; Nam CW; Cho JH; Shin WY; Seo JB; Choi SW; Lee JH; Min PK; Her SH; Lee PH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
Am J Cardiol; 2018 Feb; 121(4):423-429. PubMed ID: 29273207
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons.
Huang HP; Lin WH; Chen SG; Chen LZ; Chen MY; Che CH
Mol Neurobiol; 2017 Mar; 54(2):1456-1466. PubMed ID: 26846361
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
